FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston
- Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando
- Barclays Global Healthcare Conference on March 16 in Miami
SAN RAFAEL, Calif., March 03, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Cowen and Company 36th Annual Health Care Conference on March 8, 2016 at 8:40am ET in Boston. Management will also participate in the Raymond James 37th Annual Institutional Investors Conference on March 9, 2016 in Orlando and the Barclays Global Healthcare Conference on March 16, 2016 in Miami. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
